[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"keloids-scars\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:keloids-scars":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":24,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100624735","a-prospective-observational-clinical-study-on-exploring-the-value-of-surgical-excision-combined-with-32p-application-in-the-treatment-of-keloids-and-the-factors-affecting-the-prognosis-of-combined-therapy-100624735",false,"NCT07413497","A Prospective Observational Clinical Study on Exploring the Value of Surgical Excision Combined With 32P Application in the Treatment of Keloids and the Factors Affecting the Prognosis of Combined Therapy","Inclusion Criteria:\n\n1. Histological biopsy confirms the patient has keloids. Pathological diagnostic criteria include: 1. Proliferating fibroblasts: A large number of proliferating fibroblasts are usually detected in keloid tissue. 2. Disordered arrangement of collagen fibers: Collagen fibers in normal scars are generally arranged in an orderly manner, while in keloids, they are disorganized and present as thick bundles. 3. Scar tissue extending beyond the original wound boundaries: Keloid tissue often spreads beyond the scope of the initial trauma.\n2. Patients with keloids ≥3 mm in thickness and within 1 week after surgical excision.\n3. Patients have at least one measurable lesion as defined by the Vancouver Scar Scale (VSS) criteria.\n4. Patients have no other skin disorders similar to keloids.\n5. Patients are capable of understanding and signing the informed consent form.\n6. Patients are willing and able to comply with scheduled visits, treatment plans, laboratory tests, follow-up appointments, and other study procedures.\n\nExclusion Criteria:\n\n1. Difficulty in accurately assessing the patient's lesions.\n2. Patients who do not meet the indications for local excision or have received superficial radiotherapy after surgery.\n3. Dementia, intellectual impairment, or any mental illness that hinders the understanding of the informed consent form.\n4. Patients deemed inappropriate to participate in this clinical study by the investigator.\n5. Patients from whom pathological specimens cannot be obtained, or those who die or are lost to follow-up.\n6. Patients with recurrent keloids following previous treatment.\n7. Pregnant female patients. -","ALL",{"count":17,"type":18},401,"ESTIMATED","OBSERVATIONAL","Keloids are non-cancerous (benign) growths on the skin. They form after an injury, when the skin makes too much connective tissue that thickens and hardens.\n\nThese keloids cause big problems for people. They grow uncontrollably on their own, itch, hurt, and look bad. This is especially true if they're on visible areas like the head or neck-they harm both a person's physical comfort and mental well-being.\n\n32P application is a popular treatment for keloids. It's simple, easy to use, quick, and doesn't have many limits on where or when it can be used. Besides keloids, it also works for surface skin issues like hemangiomas.\n\nHere's how 32P works: When it breaks down (decays), it releases beta rays. These rays create a local effect that changes the shape and function of the affected tissue. Blood vessel cells in the area swell, get inflamed, and shrink, eventually blocking the blood vessels. Beta rays also stop two key things from growing too much: fibroblasts (cells that make connective tissue) and new blood vessels. This is how the treatment works-with very low chances of the keloid coming back and few side effects.\n\nFor these reasons, we think combining surgery with 32P application is an effective way to treat keloids. Its success rate is similar to, or even better than, surgery combined with low-dose radiation. Also, two factors matter a lot for how well the treatment works long-term: when 32P application is started, and the dose used.",[22,23],"Keloids","Keloids Scars",[25,26,27,28,29],"32P","keloids","32P application","nuclide application therapy","nuclide therapy","NOT_YET_RECRUITING","2026-02-09",{"date":33,"type":34},"2026-02-17","ACTUAL",{"date":36,"type":18},"2026-06-01",{"date":38,"type":18},"2030-06-01",{"name":40,"class":41},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100608454","the-efficacy-of-intralesional-bleomycin-as-compared-to-5-flourouracil-5-fu-and-triamcinolone-acetonide-tac-for-the-treatment-of-keloids-a-randomized-control-trial-100608454","NCT07201766","The Efficacy of Intralesional Bleomycin as Compared to 5-Flourouracil (5-FU) and Triamcinolone Acetonide (TAC) for the Treatment of Keloids: A Randomized Control Trial.","Inclusion Criteria:\n\n* All, patients aged 13-60 years of age, either gender enrolled for Keloid treatment under local anaesthesia.\n\nExclusion Criteria:\n\n* Allergic to bleomycin, 5-FU DIABETICS VASCULAR INSUFFICIENCY AT THE AFFECTED SITE","13 Years","60 Years",{"count":51,"type":18},104,"INTERVENTIONAL",[54],"NA","The goal of this clinical trial is to learn if drug bleomycin intralesionally is beneficial than intralesional 5FU and Triamcinolone Acetonide in treating Keloids. The main questions it aims to answer are:\n\nDoes drug Bleomycin injected intrasleisonally lower the time duration to effectively treat the keloids in participants as compared to intralesional Triamcinolone Acetonide and 5-Flourouracil? Researchers will compare drug Bleomycin and 5FU plus Triamcinolone Acetonide and determine if bleomycin is better.\n\nParticipants will:\n\nTreatment will be given in two groups by a researcher blinded of the treatment being given in each group. POSAS patient and observer scar scale will be used to assess the keloids at 0, 2, 4, 6, 8, 10, and 12 weeks and during follow ups afterwards, assessments will be carried out by another researcher who will assess the improvement on the scale of 0-no improvement, to excellent-75-100% improvement in terms of POSAS variables. Effectiveness will be indicated by 50% reduction in POSAS score from the baseline.",[23],[58,59,60],"intralesional injection","bleomycin","keloid scars","2025-11-23",{"date":63,"type":34},"2025-11-25",{"date":65,"type":18},"2025-12-02",{"date":67,"type":18},"2026-02-28",{"name":69,"class":41},"King Edward Medical University",1]